Emmanuelle Fleury

Ms. Emmanuelle Fleury

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
NHNienke Hoekstra
Nienke Hoekstra
EFEmmanuelle Fleury
Emmanuelle Fleury
TLTomas Rodrigo Merino Lara
Tomas Rodrigo Merino Lara
PBPeter van der Baan
Peter van der Baan
ABAndy Bahnerth
Andy Bahnerth
JPJean-Philippe Pignol
Jean-Philippe Pignol

17 December 2020 in Medical Physics
Verified
Journal Article
Open access
PDF file
EFEmmanuelle Fleury
Emmanuelle Fleury
PTP. Trnková
P. Trnková
EEE. Erdal
E. Erdal
MHM. Hassan
M. Hassan
BSB. Stoel
B. Stoel
MHM. Hoogeman
M. Hoogeman
Purpose: To develop a high‐resolution three‐dimensional (3D) magnetic resonance imaging (MRI)‐based treatment planning approach for uveal melanomas (UM) in proton therapy.Materials/methods: For eight patients with UM, a segmentation of the gross tumor volume (GTV) and organs‐at‐risk (OARs) was performed on T1‐ and T2‐weighted 7 Tesla MRI image data to reconstruct the patient MR‐eye. An extended contour was defined with a 2.5‐mm isotropic margin derived from the GTV. A broad beam algorithm, which we have called πDose, was implemented to calculate relative proton absorbed doses to the ipsilateral OARs. Clinically favorable gazing angles of the treated eye were assessed by calculating a global weighted‐sum objective function, which set penalties for OARs and extreme gazing angles. An optimizer, which we have named OPT’im‐Eye‐Tool, was developed to tune the parameters of the functions for sparing critical‐OARs.Results: In total, 441 gazing angles were simulated for every patient. Target coverage including margins was achieved in all the cases (V95% > 95%). Over the whole gazing angles solutions space, maximum dose (Dmax) to the optic nerve and the macula, and mean doses (Dmean) to the lens, the ciliary body and the sclera were calculated. A forward optimization was applied by OPT’im‐Eye‐Tool in three different prioritizations: iso‐weighted, optic nerve prioritized, and macula prioritized. In each, the function values were depicted in a selection tool to select the optimal gazing angle(s). For example, patient 4 had a T2 equatorial tumor. The optimization applied for the straight gazing angle resulted in objective function values of 0.46 (iso‐weighted situation), 0.90 (optic nerve prioritization) and 0.08 (macula prioritization) demonstrating the impact of that angle in different clinical approaches.Conclusions: The feasibility and suitability of a 3D MRI‐based treatment planning approach have been successfully tested on a cohort of eight patients diagnosed with UM. Moreover, a gaze‐angle trade‐off dose optimization with respect to OARs sparing has been developed. Further validation of the whole treatment process is the next step in the goal to achieve both a non‐invasive and a personalized proton therapy treatment.

5 June 2021 in Medical Physics
Verified
Journal Article
Open access
PDF file
EFEmmanuelle Fleury
Emmanuelle Fleury
PTPetra Trnková
Petra Trnková
KSKees Spruijt
Kees Spruijt
JHJoël Herault
Joël Herault
FLFranciska Lebbink
Franciska Lebbink
MHMischa Hoogeman
Mischa Hoogeman
Purpose: Eye‐dedicated proton therapy (PT) facilities are used to treat malignant intraocular lesions, especially uveal melanoma (UM). The first commercial ocular PT beamline from Varian was installed in the Netherlands. In this work, the conceptual design of the new eyeline is presented. In addition, a comprehensive comparison against five PT centers with dedicated ocular beamlines is performed, and the clinical impact of the identified differences is analyzed.Material/Methods: The HollandPTC eyeline was characterized. Four centers in Europe and one in the United States joined the study. All centers use a cyclotron for proton beam generation and an eye‐dedicated nozzle. Differences among the chosen ocular beamlines were in the design of the nozzle, nominal energy, and energy spectrum. The following parameters were collected for all centers: technical characteristics and a set of distal, proximal, and lateral region measurements. The measurements were performed with detectors available in‐house at each institution. The institutions followed the International Atomic Energy Agency (IAEA) Technical Report Series (TRS)‐398 Code of Practice for absolute dose measurement, and the IAEA TRS‐398 Code of Practice, its modified version or International Commission on Radiation Units and Measurements Report No. 78 for spread‐out Bragg peak normalization. Energy spreads of the pristine Bragg peaks were obtained with Monte Carlo simulations using Geant4. Seven tumor‐specific case scenarios were simulated to evaluate the clinical impact among centers: small, medium, and large UM, located either anteriorly, at the equator, or posteriorly within the eye. Differences in the depth dose distributions were calculated.Results: A pristine Bragg peak of HollandPTC eyeline corresponded to the constant energy of 75 MeV (maximal range 3.97 g/cm2 in water) with an energy spread of 1.10 MeV. The pristine Bragg peaks for the five participating centers varied from 62.50 to 104.50 MeV with an energy spread variation between 0.10 and 0.70 MeV. Differences in the average distal fall‐offs and lateral penumbrae (LPs) (over the complete set of clinically available beam modulations) among all centers were up to 0.25 g/cm2, and 0.80 mm, respectively. Average distal fall‐offs of the HollandPTC eyeline were 0.20 g/cm2, and LPs were between 1.50 and 2.15 mm from proximal to distal regions, respectively. Treatment time, around 60 s, was comparable among all centers. The virtual source‐to‐axis distance of 120 cm at HollandPTC was shorter than for the five participating centers (range: 165–350 cm). Simulated depth dose distributions demonstrated the impact of the different beamline characteristics among institutions. The largest difference was observed for a small UM located at the posterior pole, where a proximal dose between two extreme centers was up to 20%.Conclusions: HollandPTC eyeline specifications are in accordance with five other ocular PT beamlines. Similar clinical concepts can be applied to expect the same high local tumor control. Dosimetrical properties among the six institutions induce most likely differences in ocular radiation‐related toxicities. This interinstitutional comparison could support further research on ocular post‐PT complications. Finally, the findings reported in this study could be used to define dosimetrical guidelines for ocular PT to unify the concepts among institutions.

22 October 2014 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
TLTomas Rodrigo Merino Lara
Tomas Rodrigo Merino Lara
EFEmmanuelle Fleury
Emmanuelle Fleury
SMShahram Mashouf
Shahram Mashouf
JHJoelle Helou
Joelle Helou
CMClaire McCann
Claire McCann
JPJean-Philippe Pignol
Jean-Philippe Pignol
After breast conserving surgery, early stage breast cancer patients are currently treated with a wide range of radiation techniques including whole breast irradiation (WBI), accelerated partial breast irradiation (APBI) using high dose rate (HDR) brachytherapy, or 3D conformal radiotherapy (3D-CRT). This study compares the mean heart’s doses for a left breast irradiated with different breast techniques. An anthropomorphic Rando phantom was modified with gelatin-based breast of different sizes and tumors located medially or laterally. The breasts were treated with WBI, 3D-CRT or HDR APBI. The heart’s mean doses were measured with Gafchromic films and controlled with optically stimulated luminescent dosimeters (OSLDs). Following the model reported by Darby (16), major cardiac were estimated assuming a linear risk increase with the mean dose to the heart of 7.4% per gray. Whole breast irradiation lead to the highest mean heart dose (2.99 Gy) compared to 3D-CRT APBI, (0.51 Gy), multicatheter (1.58 Gy) and balloon HDR (2.17 Gy) for a medially located tumor. This translated into long-term coronary event increases of 22%, 3.8%, 11.7%, and 16% respectively. The sensitivity analysis showed that the tumor location had almost no effect on the mean heart dose for 3D-CRT APBI and a minimal impact for HDR APBI. For WBI large breast size and set-up errors lead to sharp increases of the mean heart dose. Its value reached 10.79 Gy for women with large breast and a set-up error of 1.5 cm. Such a high value could increase the risk of having long-term coronary events by 80%. Comparison among different irradiation techniques demonstrates that 3D-CRT APBI appears the safest one with less probability of having cardiovascular events in the future. A sensitivity analysis showed that WBI is the most challenging technique for patients with large breasts or when significant set-up errors are anticipated. In those cases additional heart shielding techniques are required.

27 April 2022 in Radiotherapy and Oncology
Verified
Journal Article
Open access
EFEmmanuelle Fleury
Emmanuelle Fleury
PTPetra Trnková
Petra Trnková
CRCaroline van Rij
Caroline van Rij
MRMyra Rodrigues
Myra Rodrigues
YKYvonne Klaver
Yvonne Klaver
MHMischa S. Hoogeman
Mischa S. Hoogeman
To investigate the potential clinical benefit of a two-beam arrangement technique using three-dimensional (3D) imaging of uveal melanoma (UM) patients treated with proton therapy and a dedicated eyeline. Retrospective CT-based treatment plans of 39 UM patients performed using a single beam (SB) were compared to plans with two beams (TB) optimized for better trade-offs in organs-at-risk sparing. The RBE-weighted prescribed dose was 60 Gy (DRBE, GTV = 60 Gy) in four fractions, assuming an RBE of 1.1. Dosimetric findings were analyzed for three patient groups based on tumor-optic nerve distance and UM staging (group GrA: ≤3 mm, T1 T2 UM; GrB: ≤3 mm, T3 UM; GrC: >3 mm, T1 T2 T3 UM). Finally, two schedules were compared on biologically effective dose (BED): both beams being delivered either the same day (TB), or on alternate days (TBalter). All strategies resulted in dosimetrically acceptable plans. A dose reduction to the anterior structures was achieved in 23/39 cases with the two-beam plans. D25% was significantly lowered compared to SB plans by 12.4 and 15.4 Gy RBE-weighted median dose in GrA and GrB, respectively. D2% was reduced by 18.6 and 6.0 Gy RBE-weighted median dose in GrA and GrB, respectively. A cost to the optic nerve was observed with a median difference up to 3.8 Gy RBE-weighted dose in GrB. BED differences were statistically significant for all considered parameters in favor of two beams delivered the same day. A two-beam strategy appears beneficial for posterior tumors abutting the optic nerve. This strategy might have a positive impact on the risk of ocular complications.

1 March 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SMShahram Mashouf
Shahram Mashouf
EFEmmanuelle Fleury
Emmanuelle Fleury
PLPriscilla Lai
Priscilla Lai
TMTomas Merino
Tomas Merino
ELEli Lechtman
Eli Lechtman
JPJean-Philippe Pignol
Jean-Philippe Pignol